Replies to post #243013 on Biotech Values

[mouton29]

I briefly listened to part of the discussion vaccine advisory panel while multitasking and heard sone favorable remarks about Novavax. I see this in a summary if the meeting at Statnews at https://www.statnews.com/2022/06/28/tracking-an-fda-advisory-panel-meeting-on-updating-covid-vaccines/

“Some fans for Novavax. Two panelists spoke out in favor of the data shown by Novavax indicating that its shot against the original strain might work well as a booster against Omicron strains. James Hildreth, CEO of Meharry Medical Colllege, said the Novavax data were “the most compelling thing I’ve seen today” and that the data seem “more impressive to me than the data for Pfizer and Moderna.” Wayne Marasco of the Dana-Farber Cancer Institute made similar comments, wondering if the Novavax data were showing the limitations of the mRNA vaccines. Hildreth encouraged the FDA to consider Novavax’s emergency use application quickly.”

The market seems to disagree, NVAX down a bit premarket.